Butters varying in trans 18:1 and cis-9,trans-11 conjugated linoleic acid modify plasma lipoproteins in the hypercholesterolemic rabbit.
The experiment was designed to study the effects of butters differing in conjugated linoleic acid (CLA) and trans 18:1 contents on lipoproteins associated with the risk of atherogenesis. New Zealand White male rabbits (9.6 weeks; 2.1 kg) were assigned for 6 or 12 weeks to three diets (n = 6 per diet) made of conventional pellets with 0.2% cholesterol and with 12% fat provided from a butter poor in trans-10 and trans-11 18:1 and in CLA (standard group), or rich in trans-10 18:1 (trans-10 18:1 group) or rich in trans-11 18:1 and in cis-9,trans-11 CLA (trans-11 18:1/CLA group). Blood samples were collected at the end of dietary treatments. Lipoproteins were separated by gradient-density ultracentrifugation. Lipid classes were determined enzymatically and apolipoproteins A-I and B by radial immunodiffusion. Mainly in the 12-week rabbits, higher plasma triglycerides and apolipoprotein B levels shown in the standard and trans-10 18:1 groups compared with those in the trans-11 18:1/CLA group are associated with higher plasma levels of very low density lipoproteins (VLDL) and low density lipoproteins (LDL) also shown in these two groups. In the 12-week rabbits, a shift towards denser LDL, considered as more atherogenic, was shown only in the trans-10 18:1 group. In these animals, the VLDL + LDL to HDL ratio was 1.7-2.3 times higher in the trans-10 18:1 group than in the other groups (P = 0.076). These results suggest a rather neutral effect of trans-11 18:1/CLA butter towards the risk of atherogenesis, whereas trans-10 18:1 butter would tend to be detrimental.
Bauchart
Dominique
D
UR1213 Herbivores, Research Unit on Herbivores, Nutrients and Metabolisms Group, INRA, Site de Theix, Saint-Genès-Champanelle, France. bauchart@clermont.inra.fr
Roy
Alexandre
A
Lorenz
Stephanie
S
Chardigny
Jean-Michel
JM
Ferlay
Anne
A
Gruffat
Dominique
D
Sébédio
Jean-Louis
JL
Chilliard
Yves
Y
Durand
Denys
D
D000818:Animals; D001053:Apolipoproteins / Q000097:blood; D002079:Butter / Q000032:analysis*; D002784:Cholesterol / Q000097:blood; D006937:Hypercholesterolemia / Q000097:blood*; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D011817:Rabbits; D044242:Trans Fatty Acids / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D014461:Ultracentrifugation
D001053:Apolipoproteins; D044243:Linoleic Acids, Conjugated; D008055:Lipids; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D044242:Trans Fatty Acids; C046938:9,11-linoleic acid; D002079:Butter; D002784:Cholesterol